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Abstract
Background: Pivotal trials, the clinical studies that inform U.S. Food and Drug Administration (FDA) approval
decisions, provide the foundational evidence supporting the safety and efficacy of novel therapeutics. We
determined the representation of the elderly, women, and patients from racial and ethnic minorities in pivotal trials
and whether the FDA is making subgroup efficacy analyses among these subpopulations available to the public.
Methods: We conducted a cross-sectional study of novel therapeutics approved by the FDA between 2011 and
2013. Using publicly available FDA documents, we collected information on the demographic characteristics of
pivotal trial participants (age ≥65 years, sex [male, female], race [white, black, Asian, other], and ethnicity [Hispanic,
non-Hispanic]) and determined the availability of subgroup analyses by age, sex, race, and ethnicity.
Results: We identified 86 novel therapeutic that were approved by the FDA between 2011 and 2013 for 92
indications on the basis of 206 pivotal trials. The median age of pivotal trial patients was 53.1 years (interquartile
range 40.6–60.6), and the mean proportion of patients ≥65 years of age was 28.9 % (95 % CI 23.5–34.4 %). Similar
proportions of pivotal trial participants were male (mean 50.3 %, 95 % CI 45.3–55.2 %) and female (mean 49.7 %,
95 % CI 44.7–54.7 %). Most participants were white (mean 79.2 %, 95 % CI 75.9–82.6 %), while the mean proportion
of black patients was 7.4 % (95 % CI 5.5–9.3 %), that of Asian patients was 7.4 % (95 % CI 5.2–9.7 %), and that of
patients of other races was 5.9 % (95 % CI 4.4–7.5 %). Information about ethnicity was available for only 59.8 % of
indications, and where such data were available, the mean proportion of Hispanic participants was 13.3 % (95 % CI
10.3–16.3 %). FDA reviewers performed and made available subgroup efficacy analyses by age, sex, and race for at
least one of the pivotal trials used as the basis of approval for over 80 % of indications.
Conclusions: Although women are equally represented in pivotal trials supporting recent novel therapeutic
approvals by the FDA, elderly patients and those from racial and ethnic minorities are underrepresented. FDA
reviewers generally perform subgroup efficacy analyses by age, sex, and race and make these subgroup analyses
available to the public.
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Background
Clinical trials provide the foundational evidence that sup-
ports U.S. Food and Drug Administration (FDA) approval
and informs physicians and patients as they make decisions
about the use of new therapies. For this evidence to inform
both regulators and clinical practice, it is critical that the
patients participating in these trials, wherever they are con-
ducted, reflect the population of patients expected to use
the novel therapeutic agent. This is particularly important
for pivotal clinical trials, the late-stage clinical trials that are
intended to demonstrate the safety and efficacy of novel
therapeutics and upon which the FDA bases its approval
decisions [1]. However, several groups of individuals, in-
cluding the elderly, women, and persons from racial and
ethnic minority groups, have historically been underrepre-
sented in clinical research, limiting the ability of many stud-
ies to inform decisions about their care [2–8].
Over the years, the FDA has taken several measures
aimed at improving and ensuring the representativeness of
patients participating in pivotal clinical trials. First, in 1998,
the FDA issued the “demographic rule,” requiring drug
makers to report the age, sex, and race of clinical trial par-
ticipants in their annual reports to the agency [9]. While
the demographic rule ensured that this information was
available to the FDA, it did not mandate its availability to
the public. However, the 2012 FDA Safety and Innovation
Act (FDASIA) urged the FDA to address this issue, and, in
August 2013, the agency released a report describing the
demographic characteristics of participants in trials of drugs
and devices approved in 2011, as well as the availability of
subgroup analyses for key age, sex, and race subgroups
[10]. More recently, the FDA published an expanded inves-
tigation of the representativeness of clinical trials support-
ing drugs approved between 2010 and 2012 [11].
In this article, we describe the results of our re-
search to characterize the demographic characteris-
tics of patients participating in pivotal clinical trials
for all novel therapeutics approved by the FDA be-
tween 2011 and 2013 and to determine the availabil-
ity of subgroup efficacy analyses using publicly
available data sources. Our research was similarly fo-
cused on participation in these trials by members of
historically underrepresented populations: the elderly
(defined as patients aged 65 years or older), women,
persons of nonwhite race, and Hispanics. Although
our study was initiated before the publication of the
FDA’s initial report prompted by the FDASIA and
subsequent research study [10, 11], there are three
specific reasons that support the current dissemin-
ation of our work: (1) to validate the FDA’s findings
of the age, sex, and race of clinical trial participants,
exclusively using publicly available data sources,
since the FDA’s study made use of internal docu-
ments submitted to the agency that are not available
to the public; (2) to confirm the FDA’s findings
among 2013 drug approvals, since the FDA’s study
focused on 2010 through 2012 approvals; and (3) to
provide a broader investigation of the issue by exam-
ining trial participation by ethnicity, since the FDA
study focused only on age, sex, and race.
Methods
Study sample
Using the Drugs@FDA database, a publicly available
index of FDA regulatory actions, we identified all
novel therapeutics (i.e., new molecular entities—-
drugs—and novel biologics) that were approved by
the FDA between 1 January 2011 and 31 December
2013 [12]. Generic drugs, reformulations, combina-
tions of nonnovel therapeutic agents, and nonthera-
peutic agents (i.e., diagnostic agents) were excluded.
For each of the novel therapeutics included in our
sample, we determined the indications for which it
was first approved for use by reviewing the FDA’s
approval letter and the initial drug label. All indica-
tions were classified into one of eight therapeutic
areas (cancer, cardiovascular [including diabetes mel-
litus and hyperlipidemia], infectious disease, auto-
immune and musculoskeletal disease, neurology,
dermatology, psychiatry, and other). Next, we deter-
mined whether these novel therapeutics had been
granted orphan status, indicating that they are pri-
marily intended for the treatment of a rare disease.
For small molecules, orphan status was determined
using the Drugs@FDA database [12]; for biologics,
we searched the Orphan Drug Product Designation
Database [13].
Pivotal trials
The FDA makes a series of documents available in the
Drugs@FDA database that correspond to the key compo-
nents of the agency’s review process, explain the basis of
its approval decision, and summarize notable information
presented in sponsors’ applications. The “medical review”
discusses the safety and efficacy of novel therapeutics, de-
scribing the pivotal trials in detail. For each of the novel
therapeutics included in our sample, we manually
searched the corresponding medical review documents to
identify the pivotal trials that supported their approval
and recorded the intention-to-treat (ITT) population (i.e.,
all participants who received at least one dose of the study
drug or its comparator). If the medical review did not
clearly identify the pivotal trials used as the basis of ap-
proval, we reviewed other FDA documents to identify
such trials, such as the summary review and office director
memos, and if necessary manually classified trials as piv-
otal following an established approach [1].
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Demographic characteristics of pivotal trial participants
Information describing the age, sex, race, and ethni-
city of the participants in each of the identified piv-
otal trials was abstracted from the FDA’s medical
review documents. In circumstances when the med-
ical review did not contain all of this information,
the agency’s statistical reviews were searched. To
characterize the ages of pivotal trial participants, we
recorded the mean as a summary statistic; if the
mean was unavailable, the median was used. When
FDA documents provided such statistics for individ-
ual trial arms, but not in the aggregate, we used a
weighted-average approach to estimate the corre-
sponding statistic for the entire study population. In
addition, we determined the number of elderly clin-
ical trial participants, defined as those aged 65 years
or older. Next, we recorded the number of male and
female participants in each study. To characterize
clinical trial participants’ race and ethnicity, we
counted the number of participants in four racial
subgroups (white, black, Asian, and other) and two
ethnic subgroups (Hispanic and non-Hispanic). Two
reviewers (JHN and JAA) independently abstracted
this information from FDA documents. A second re-
viewer (NSD) validated the initial abstraction by
reabstracting all data, and all discrepancies were re-
solved through discussion with the senior investiga-
tor (JSR).
Availability of subgroup efficacy analyses
To determine whether FDA reviewers documented
the efficacy of novel therapeutics for age, sex, and
race as well as ethnic subgroups, we searched the
medical and statistical reviews to identify the pres-
ence of subgroup analyses for each pivotal trial. Ana-
lyses of efficacy involving patients of any two age
groups (e.g., <40 years vs. ≥40 years; <65 years vs.
≥65 years) were considered to represent a subgroup
analysis by age. We considered an acknowledgement
of insufficient sample size in certain subgroups to
represent subgroup analysis because the agency
made an attempt to produce this information.
Statistical analysis
For each pivotal trial, we computed the proportions
of patients in various age (≥65 years), sex (male, fe-
male), race (white, black, Asian, other), and ethnicity
(Hispanic, non-Hispanic) subgroups. Next, to reflect
the overall demographic composition of the clinical
development program for each novel therapeutic, we
aggregated these data, which describe the character-
istics of patients participating in individual pivotal
trials, to the indication level. To do this, we
weighted the contribution from each pivotal trial
according to its ITT population. In cases where cer-
tain data fields were available for some but not all of
the pivotal trials supporting an indication, we aggre-
gated only data from trials for which the field was
available; for fields that were not available for any
pivotal trials within an indication, we noted that the
data were missing.
After aggregating this information to the indication
level, we characterized the demographic composition
of pivotal trial patients using descriptive statistics,
reporting the median and interquartile range (IQR)
for age and computing the mean proportion of pa-
tients in the various age, sex, race, and ethnicity
subgroups with the corresponding 95 % CIs. In
addition, we performed a stratified analysis by thera-
peutic area and orphan status. To contextualize our
results, we also computed summary statistics for the
corresponding demographics of the U.S. population
using data derived from 2010 U.S. Census [14]. Last,
we counted the number of indications for which
analyses of efficacy in age, sex, race, and ethnicity
subgroups were documented in the FDA’s review of
at least one of the associated pivotal trials.
Since the epidemiology of a disease may preclude re-
cruitment of pivotal trial participants of differing ages,
sexes, races, and ethnicities, we repeated all analyses
after excluding those therapeutics indicated for diseases
that are uncommon among historically underrepre-
sented populations, including the elderly, females, and
racial and ethnic minorities. For instance, a pivotal trial
for a novel therapeutic used to treat prostate cancer
would not be expected to recruit women. To identify
such therapeutics, two investigators (NSD and JSR) inde-
pendently reviewed the indications for which each novel
therapeutic was initially approved and, based on their
clinical experience, excluded those where the disease
prevalence in the four historically underrepresented pop-
ulations was approximately less than half the disease
prevalence among the “majority” populations. As an-
other example, ivacaftor, a drug for the treatment of cys-
tic fibrosis, a disease that affects primarily young white
individuals, was excluded from analyses examining age,
race, and ethnicity subgroups, because it is unrealistic to
expect that pivotal trials involving this drug would in-
clude elderly, nonwhite, or Hispanic patients. (For a
complete list of therapeutic subgroup population exclusions,
see Tables 5, 6 and 7 in Appendix). All data were collected
and analyzed using Microsoft Excel software (Microsoft,
Redmond, WA, USA). Statistical analysis was performed
using JMP software (SAS Institute, Cary, NC, USA).
Results
We identified 89 novel therapeutics that the FDA approved
between 2011 and 2013 for use in 97 indications. (For
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details of sample construction, see Fig. 2 in the Appendix)
After removing therapeutics and indications that were ap-
proved in the absence of a pivotal trial, our final sample
consisted of 86 therapeutics approved for use in 92 indica-
tions. Of these 86 therapeutics, 27 (31.4 %) were approved
in 2011, 35 (40.7 %) in 2012, and 24 (27.9 %) in 2013
(Table 1). Drugs approved for indications in cancer
(30.4 %), cardiovascular disease (12.0 %), and infectious dis-
ease (9.8 %) accounted for over half of approvals, while 30
(32.6 %) indications received orphan status.
The 92 indications were approved on the basis of 206
pivotal trials that included a total of 174,855 patients. The
number of pivotal trials supporting each approval varied: 41
(44.6 %) indications were approved on the basis of a single
pivotal trial, 28 (30.4 %) on the basis of two pivotal trials,
and 23 (25.0 %) on the basis of three or more pivotal trials.
When aggregated to the indication level, the mean number
of patients enrolled in the pivotal trials supporting each ap-
proved indication was 1900 (standard deviation 3156).
Demographic characteristics of pivotal trial participants
At the indication level, the median age of pivotal trial pa-
tients was 53.1 years (IQR 40.6–60.6) (Table 2). Subgroup
categorization of participants’ age was available for at least
one trial supporting 61 (66.3 %) of 92 indications, and
among these indications, the mean proportion of patients
aged ≥65 years was 28.9 % (95 % CI 23.5–34.4 %). For 9 in-
dications (14.5 %), more than half of the patients were aged
65 years or older (Fig. 1). Of the 92 indications, 22 (23.9 %)
are used to treat diseases that are uncommon in the elderly.
When we limited our analyses to indications for which the
inclusion of the elderly should be expected, we found fairly
consistent results (Table 2).
Information about the sex of clinical trial participants
was universally available, and equal proportions of clinical
trial participants were male (50.3 %, 95 % CI 45.3–55.2 %)
and female (49.7 %, 95 % CI 44.7–54.7 %), although there
was variation: in 12.0 % of indications, over 80 % of patients
were female, and in 9.8 % of indications, over 80 % were
male. Of the 92 indications, 14 (15.2 %) are used to treat
diseases that are uncommon in women. When we limited
our analyses to indications for which the inclusion of
women should be expected, we found fairly consistent re-
sults (Table 2).
Approximately 80 % of clinical trial participants were
white (79.2 %, 95 % CI 75.9–82.6 %), while 7.4 % (95 %
CI 5.5–9.3 %) were black, 7.4 % (95 % CI 5.2–9.7 %)
were Asian, and 5.9 % (95 % CI 4.4–7.5 %) were of other
races. When compared with the overall U.S. population,
more patients participating in clinical trials included in
our study were white (79.2 % vs. 75.2 %) and Asian
(7.4 % vs. 5.4 %), while fewer patients were black (7.4 %
vs. 13.2 %). Nonwhite patients comprised 30 % or more
of the clinical trial participants for almost one-fourth of
indications (22 of 92, or 23.9 %). In contrast to informa-
tion about the age, sex, and race of clinical trial partici-
pants, which was almost always available, information
about the ethnicity of clinical trial participants was avail-
able for only 55 (59.8 %) of 92 indications. Among indi-
cations where these data were reported, 13.3 % (95 % CI
10.3–16.3 %) were Hispanic, which is less than the
16.2 % of the overall U.S. population. Hispanic partici-
pants comprised 20 % or less of participants in clinical
trials supporting the approval of 81.8 % (45 of 55) of in-
dications where ethnicity information was reported. Of
the 92 indications included in this analysis, 14 (15.2 %)
are used to treat diseases that are uncommon in racial
minorities. When we limited our analyses to indications
for which the inclusion of patients from racial minorities
should be expected, we found fairly consistent results
(Table 2).
Table 1 Novel therapeutic agents and Associated Indications
Approved by the U.S. Food and Drug Administration between
2011 and 2013
Number (%)
Novel therapeutics, n = 86
Approval year
2011 27 (31.4 %)
2012 35 (40.7 %)
2013 24 (27.9 %)
Number of approved indications
One 80 (93.0 %)
Two 5 (5.8 %)
Three 1 (1.2 %)
Associated indications, n = 92
Therapeutic area
Cancer 28 (30.4 %)
Cardiovascular disease, diabetes mellitus, hyperlipidemia 11 (12.0 %)
Infectious disease 9 (9.8 %)
Autoimmune and musculoskeletal 4 (4.3 %)
Neurology 7 (7.6 %)
Dermatology 5 (5.4 %)
Psychiatry 2 (2.2 %)
Other 26 (28.3 %)
Orphan status
Yes 30 (32.6 %)
No 62 (67.4 %)
Number of pivotal trials
One 41 (41.6 %)
Two 28 (30.4 %)
Three 11 (12.0 %)
Four 12 (13.0 %)
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Pivotal trial participants by therapeutic area
There was significant variation in the characteristics
of patients participating in clinical trials according to
therapeutic area (Table 3). Pivotal trials involving
therapies for cancer tended to involve higher propor-
tions of elderly patients than those for other indica-
tions (36.6 % [95 % CI 27.6–45.6 %] vs. 23.9 %
[95 % CI 17.3–30.6 %]), higher proportions of white
patients (82.6 % [95 % CI 76.4–88.8 %] vs. 77.8 %
[95 % CI 73.7–81.8 %]), and lower proportions of
Hispanic patients (3.3 % [95 % CI 0.5–6.0 %] vs.
10.0 % [95 % CI 7.1–12.9 %]). Male patients were
more common in pivotal trials of therapies for infec-
tious diseases than for other indications (66.2 %
[95 % CI 55.5–76.8 %] vs. 48.6 % [95 % CI 43.2–
53.9 %]), and a far higher proportion of black pa-
tients also participated in such trials (16.7 % [95 %
CI 8.7–24.7 %] vs. 9.5 % [95 % CI 4.5–8.3 %]).
Pivotal trial participants by orphan status
The age and sex of participants in clinical trials involving
therapies receiving orphan status tended to be similar to
those that did not receive orphan status. Although there
were comparable proportions of white patients participat-
ing in clinical trials of drugs receiving orphan status, the
proportion of black patients was lower (5.4 % [95 % CI 2.8–
8.2 %] vs. 8.3 % [95 % CI 5.8–10.9 %]), while the proportion
of Asian patients was higher (10.6 % [95 % CI 4.9–16.4 %]
vs. 5.9 % [95 % CI 3.8–7.9 %]). Hispanic patients tended to
be underrepresented in clinical trials involving therapies re-
ceiving orphan status. The mean proportions of Hispanic
patients were 10.9 % (95 % CI 4.1–17.6 %) for therapies
with orphan status compared with 14.1 % (95 % CI 10.6–
17.5 %) for therapies without orphan status.
Availability of subgroup efficacy analyses
FDA reviewers generally performed subgroup efficacy
analyses by age, sex, and race for at least one of the
pivotal trials used as the basis of approval for most
indications included in our sample (Table 4). Specif-
ically, subgroup analyses by age were performed for
85 (92.4 %) of 92 indications, by sex for 80 (87.0 %)
of 92 indications, and by race 74 (80.4 %) of 92 indi-
cations. In contrast, subgroup analyses by ethnicity
were performed in 21 (22.8 %) of 92 indications.
After removing indications involving disease pro-
cesses that are uncommon in the elderly, females,
and racial minorities, the rates with which the FDA
reviewer performed subgroup analyses were consist-
ent by age, sex, and race, but rose slightly.
Table 2 Characteristics of participants in pivotal trial aggregated at the indication level providing the basis of U.S. Food and Drug
Administration approval of novel therapeutic agents between 2011 and 2013




Medianb (IQR) 53.1 (40.6–60.6) 56.4 (50.5–62.5) 37.2 (n/a)
Aged ≥65 yearsc, proportion of patients (95 % CI) 28.9 % (23.5–34.4 %) 32.6 % (26.9–38.4 %) 13.0 %
Sex, proportion of patients (95 % CI)
Male 50.3 % (45.3–55.2 %) 46.4 % (41.8–50.9 %) 49.2 %
Female 49.7 % (44.7–54.7 %) 53.6 % (49.0–58.2 %) 50.8 %
Race, proportion of patients (95 % CI)
White 79.2 % (75.9–82.6 %) 77.7 % (74.3–81.2 %) 72.5 %
Black 7.4 % (5.5–9.3 %) 8.0 % (6.0–10.0 %) 13.2 %
Asian 7.4 % (5.2–9.7 %) 7.9 % (5.4–10.3 %) 5.4 %
Otherd 5.9 % (4.4–7.5 %) 6.4 % (4.7–8.0 %) 8.8 %
Ethnicity, proportion of patientse (95 % CI)
Hispanic 13.3 % (10.3–16.3 %) n/a 16.3 %
Non-Hispanicd 86.7 % (83.7–89.7 %) n/a 83.7 %
n/a not applicable
aIncludes only those indications for which the prevalence of the disease is evenly spread across patients of all ages, sexes, or races. Indications for which the
prevalence in three key demographic subgroups (age ≥65 years, female sex, nonwhite race) is less than half that of the prevalence among other patients
were excluded.
bMean age was unavailable for 28 trials. In these cases, we assumed that the median age, which was universally reported for these trials, approximated the mean.
cIncludes patients in subgroups defined as >65 as well as ≥65 years old. Age breakdown was not available for 31 (33.7 %) of 92 in overall analysis and 19 (27.1 %)
of 70 in the sensitivity analysis.
dIncludes patients whose race/ethnicity was not explicitly defined
eEthnicity information was not available for 37 (40.2 %) of 92 indications in overall analysis. Sensitivity analysis by ethnicity was not performed.
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Discussion
Our characterization of the demographic characteristics
of patients participating in pivotal trials for all novel
therapeutics approved by the FDA between 2011 and
2013 demonstrates that female patients, and to a certain
extent elderly patients, appear to be appropriately rep-
resented, while black and Hispanic patients remain un-
derrepresented. Specifically, we found that elderly
patients made up between one-fourth and one-third of
all pivotal trial participants and that the proportion of
participating male and female patients was equal. White
patients accounted for almost 80 % of pivotal trial par-
ticipants, a higher proportion than in the general popu-
lation; in contrast, between 5 % and 10 % of patients
participating in pivotal trials were black, far less than
their representation in the general population, and
similarly low rates of participation were observed for
Hispanic patients. Last, we found that the FDA’s sub-
group efficacy analyses by age, sex, and race were usu-
ally but not always provided within publicly available
documents, while such analyses by ethnicity were
seldom available.
Our results suggest that information describing the
sex of pivotal trial participants is being made avail-
able within FDA documentation and that women are
equally represented in more recently conducted piv-
otal clinical trials. These findings suggest that pro-
gress has been made since the early 2000s, when the
participation of women in clinical research was lim-
ited [3, 4, 6–8]. For example, in our present study
we found that among therapeutics approved for car-
diovascular disease, almost 45 % of participants in
pivotal trials were female; in contrast, women com-
prised only 30 % of the trials used to inform the
American Heart Association’s 2007 guideline for the
prevention of cardiovascular disease [15].
Similarly, it appears that more elderly patients are
being recruited to participate in clinical trials than in
the past; however, rates are still unlikely to approxi-
mate disease burden. For example, the proportion of
Fig. 1 Number of pivotal trials that supported the approval of novel therapeutics approved between 2011 and 2013, by the proportion of
participating elderly, female, nonwhite and Hispanic patients
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Table 3 Characteristics of participants in pivotal trials at the indication level providing the basis of U.S. Food and Drug Administration approval of novel therapeutic agents
between 2011 and 2013, stratified by indication-level characteristics
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elderly patients in pivotal trials involving novel thera-
peutics for cancer was approximately 36 %. While this
represents an improvement over trials conducted be-
tween 1996 and 1998, in which elderly patients
accounted for 25 % of participants [5], the age-
adjusted incidence rate of cancer is 10 times higher
among those aged 65 years or older [16].
In contrast, we observed that the proportion of
black patients participating in pivotal trials was rela-
tively low, below rates that would be expected given
the general population and well below rates that
would be expected given disparities in disease bur-
den, as minority populations are more likely to be
diagnosed with many known diseases, including can-
cer, heart disease, and diabetes [17]. This finding in-
dicates that racial disparities in clinical research
participation that have been noted in the 1990s and
2000s likely persist today [4, 5, 8]. The limited
reporting of ethnicity information and the apparent
underrepresentation of Hispanic patients may reflect
the fact that only in 2005 did the FDA clarify its ex-
pectation that pivotal trial participant ethnicity be
documented [18]. Nevertheless, little is known about
the study of historically underrepresented minorities
in clinical trials after FDA approval, suggesting that
the FDA approval itself offers an important oppor-
tunity to ensure adequate representation of pivotal
trial populations.
Our findings validate the FDA’s research that char-
acterized the demographic characteristics of partici-
pants in pivotal trials of drugs approved between
2010 and 2012 [10, 11] and demonstrate that the ob-
servations made in the agency’s analyses extend to
drugs approved in 2013. We found that the availabil-
ity of subgroup analyses of efficacy by age, sex, and
race was slightly lower in our study than the FDA’s
and could be explained by the FDA’s use of
nonpublic data sources. In the aggregate, our study
and the FDA’s research indicate that it may be pos-
sible for the agency to do more to encourage the
participation of the elderly and racial and ethnic mi-
norities in pivotal trials. However, the inclusion of
such patients in clinical trials is not enough; sub-
group efficacy analyses ought to be made more easily
available to the public, rather than just in the
agency’s lengthy review documents. The FDA took
an important step forward in August 2014 by releas-
ing an action plan to address the issue of demo-
graphic subgroup participation and the availability of
the associated data [19]. In addition, the launch of
the FDA’s “Drug Trials Snapshot” website provides
straightforward information about the demographic
characteristics of pivotal trial participants and the re-
sults of subgroup analyses of efficacy; however, this
useful tool is available for only a handful of drugs at
the moment [20].
There are several important limitations of this
study to consider. First, we describe the demographic
characteristics of participants in pivotal trials only.
While these trials represent the primary source of
information characterizing the safety and efficacy of
novel therapeutics, it is possible that the demo-
graphic composition of other trials, which were not
considered to be as important to regulators, may be
different and could potentially include higher pro-
portions of elderly and female patients as well as
those from racial and ethnic minorities. Second, our
analysis was focused on the public availability of in-
formation about the demographic characteristics of
patients participating in clinical trials. Since applica-
tions submitted to the FDA are not available to the
public, the agency may have additional insight into
the demographics of pivotal trial participants that
are not described in its publicly available review doc-
uments, which were the basis of our study. More-
over, any information is made available for only
therapeutics approved by the FDA; we were unable
to examine the demographic characteristics of partic-
ipants in pivotal trials of unapproved therapeutics.
Third, we did not determine whether the FDA sub-
group efficacy analysis identified differences among
population subgroups, only whether the analysis was
performed. Nor did we determine whether the FDA
conducted subgroup safety analyses, which the FDA
should consider as part of new drug evaluations as
directed by the FDASIA.
Fourth, our assessments of the representativeness
of patients participating in clinical trials were neces-
sarily crude and relied on comparisons with the
demographics of the overall U.S. population. Ideally,
the characteristics of pivotal trial participants would
Table 4 Availability of at least one subgroup analysis for
each indication associated with novel therapeutic agents
approved by the U.S. Food and Drug Administration









Age 85/92 (92.4 %) 65/70 (92.9 %)
Sex 80/92 (87.0 %) 76/84 (90.5 %)
Race 74/92 (80.4 %) 73/84 (86.9 %)
Ethnicity 21/92 (22.8 %) n/a
aIncludes only those indications for which the prevalence of the disease is
evenly spread across patients of all ages, sexes, or races. Indications for which
the prevalence in three key demographic subgroups (age ≥65 years, female
sex, nonwhite race) was less than half that of the prevalence among other
patients were excluded.
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be compared with the age, sex, race, and ethnicity of
the population of patients affected by the disease for
which each novel therapeutic was indicated; however,
with the exception of cancer, such detailed epidemio-
logical data are not systematically available. Fifth, the
location of the sites where these clinical trials were
conducted may influence the demographic compos-
ition of pivotal trial participants. Information on lo-
cations of clinical trial sites was not systematically
available in the FDA documents, such that we were
unable to characterize clinical trial participants on
the basis of clinical trial site locations. While many
consider drug development and evaluation to be a global
enterprise, the demographics of the pivotal trial partici-
pants should be reasonably expected to reflect the U.S. pa-
tient population for whom the therapeutic is being
approved for use. We cannot be certain whether our find-
ings suggesting that more elderly patients are being re-
cruited to participate in clinical trials than in the past, but
that black and Hispanic patients remain underrepresented,
are a consequence of greater trial recruitment from non-
U.S. countries or other reasons. Last, in our present study,
we relied on the demographic data reported in FDA docu-
ments. It is not known what methods were used to ascer-
tain this demographic data, originally collected by each
manufacturer, or whether the data collection process was
standardized across manufacturers. However, the FDA
does suggest that patients participating in clinical trials
self-report their race and ethnicity [18].
Conclusions
Although women are equally represented in pivotal trials
supporting recent novel therapeutic approvals by the
FDA, elderly patients and those from racial and ethnic
minorities are underrepresented. FDA reviewers gener-
ally perform subgroup analyses by age, sex, and race and
make these subgroup analyses available to the public,
but not in the most accessible formats. More can be
done to ensure adequate representation of pivotal trial
populations to inform clinical decision-making at the
time of drug approval.
Appendix
Table 5 Indications excluded from selected analysesa on the
basis of disproportionately low disease prevalence among those
aged ≥65 years
Drug Indication
Rilpivirine hydrochloride Human immunodeficiency Virus
Spinosad Lice
Telaprevir Hepatitis C
Brentuximab vedotin Hodgkin lymphoma
Table 5 Indications excluded from selected analysesa on the
basis of disproportionately low disease prevalence among those
aged ≥65 years (Continued)




Lucinactant Respiratory distress syndrome
Taliglucerase alfa Gaucher disease
Ivacaftor Cystic fibrosis
Crofelemer Patients with diarrhea and Human
immunodeficiency Virus infection
on antiretroviral therapy





Lomitapide mesylate Homozygous familial
hypercholesterolemia
Mipomersen sodium Homozygous familial
hypercholesterolemia
Dimethyl fumarate Relapsing remitting multiple
sclerosis
Macitentan Pulmonary arterial hypertension
(WHO group 1)
Dolutegravir sodium Human immunodeficiency Virus
Riociguat Persistent/recurrent CTEPH (WHO
group 4) after surgery or inoperable
CTEPH to improve exercise capacity
and WHO functional class
Riociguat Pulmonary arterial hypertension
(WHO group 1) to improve exercise
capacity, WHO class, delay functional
worsening
Simeprevir sodium Hepatitis C
CTEPH chronic thromboembolic pulmonary hypertension, SLE systemic lupus
erythematosus, WHO World Health Organization
aAs described in detail within the main text
Table 6 Indications excluded from selected analysesa on the
basis of disproportionately low disease prevalence among
females
Drug Indication
Rilpivirine hydrochloride Human immunodeficiency Virus
Abiraterone acetate Prostate cancer
Avanafil Erectile dysfunction
Enzalutamide Prostate cancer
Crofelemer Patients with diarrhea and HIV




Radium Ra-223 dichloride Prostate cancer
Dolutegravir sodium Human immunodeficiency Virus
aAs described in detail within the main text
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